- Home
- SWIM vs EYPT Comparison
SWIM vs EYPT Comparison
Compare SWIM & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- EYPT
- Stock Information
- Founded
- SWIM 1956
- EYPT 1987
- Country
- SWIM United States
- EYPT United States
- Employees
- SWIM N/A
- EYPT N/A
- Industry
- SWIM Plastic Products
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- SWIM Industrials
- EYPT Industrials
- Exchange
- SWIM Nasdaq
- EYPT Nasdaq
- Market Cap
- SWIM 895.0M
- EYPT 741.0M
- IPO Year
- SWIM 2021
- EYPT 2005
- Fundamental
- Price
- SWIM $7.51
- EYPT $13.98
- Analyst Decision
- SWIM Hold
- EYPT Strong Buy
- Analyst Count
- SWIM 3
- EYPT 6
- Target Price
- SWIM $6.93
- EYPT $25.83
- AVG Volume (30 Days)
- SWIM 520.0K
- EYPT 1.1M
- Earning Date
- SWIM 11-04-2025
- EYPT 11-06-2025
- Dividend Yield
- SWIM N/A
- EYPT N/A
- EPS Growth
- SWIM N/A
- EYPT N/A
- EPS
- SWIM N/A
- EYPT N/A
- Revenue
- SWIM $521,828,000.00
- EYPT $51,898,000.00
- Revenue This Year
- SWIM $9.17
- EYPT N/A
- Revenue Next Year
- SWIM $5.38
- EYPT N/A
- P/E Ratio
- SWIM N/A
- EYPT N/A
- Revenue Growth
- SWIM N/A
- EYPT 2.99
- 52 Week Low
- SWIM $4.56
- EYPT $3.91
- 52 Week High
- SWIM $8.46
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- SWIM 46.57
- EYPT 58.55
- Support Level
- SWIM $7.27
- EYPT $13.00
- Resistance Level
- SWIM $7.72
- EYPT $14.04
- Average True Range (ATR)
- SWIM 0.27
- EYPT 0.93
- MACD
- SWIM -0.02
- EYPT -0.08
- Stochastic Oscillator
- SWIM 48.96
- EYPT 60.34
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.